Three-year results from world’s first long-term clinical trial in earliest stage of Alzheimer’s disease


Sydney, Australia: The much anticipated 3-year results from the LipiDiDiet (LDD) Study – the world’s first independently run, peer reviewed EU-funded clinical trial to investigate the effects of nutritional drink Souvenaid® in patients with pre-dementia stage Alzheimer’s Disease (AD) known also as Mild Cognitive Impairment (MCI) – show for the first time that a nutritional intervention has been clinically proven to help sustain memory and cognition in the long-term when taken daily over 3 years.

Just published in the peer-reviewed publication Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association,the findings conclude that taken daily, Souvenaid® – a specific combination of fatty acids, vitamins and other nutrients available in Australia via GPs and pharmacists – is clinically proven to slow progression of early AD including MCI in multiple aspects including slowing the progression of memory and cognitive decline by 60 per cent.

The clinical data also indicates that Souvenaid reduced brain shrinkage by 33 per cent and reduced the loss of everyday task performance by 45 per cent.1

These results are incredibly important because currently there are no approved treatment options for Mild Cognitive Impairment (MCI) in Australia.

Associate Professor Michael Woodward AM, University of Melbourne

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length.